Rachel C. Jankowitz

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025

Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Reporting on invasive lobular breast cancer in clinical trials: a systematic review

International survey on invasive lobular breast cancer identifies priority research questions

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

<i>BRCA1</i>and<i>BRCA2</i>pathogenic sequence variants in women of African origin or ancestry

Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence